Given the efficacy of anti‐VEGF in suppressing CNV, future clinical strategies might explore the potential synergistic effects of combining PD‐L1 and anti‐VEGF therapies, potentially mirroring dual‐specificity antibody treatments used in cancer therapy.[86] Additionally, the cellular distribution of VEGF signaling warrants further exploration to fully understand its role in the CNV. Here, VEGFA is linked to cancer.